ClinicalTrials.gg
Enrolling by invitationNCT07710508Updated Jul 23, 2026

Difference in Incontinence Prevalence Between High Impact Athletes, Low Impact Athletes and Sedentary Subjects

An observational study in Urinary Incontinence (UI) and Urinary Incontinence , Stress, sponsored by University of Valencia. Enrolling by invitation at 1 site in Spain. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-23.

Primary conditionUrinary Incontinence, StressRegistry: Urinary IncontinenceReclassifiedWhy we changed it
Registry
Urinary Incontinence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Urinary Incontinence, Stress
Why
  1. The study's listed conditions name Urinary Incontinence, Stress, a narrower term within Urinary Incontinence.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Valencia · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
270
Ages
18 Years to 35 Years
Sex
All
01

Study summary

This observational cross-sectional study aims to investigate the association between participation in high-impact sports, physical activity level, and urinary incontinence in young adults. The study will compare six groups based on sex and physical activity level: male and female high-impact sports participants, physically active males and females who do not participate in high-impact sports, and sedentary males and females.

Participants aged 18-35 years will undergo a single assessment including sociodemographic and medical information, physical activity assessment, urinary incontinence questionnaires, sport-related characteristics, psychosocial questions regarding the influence of social taboos on questionnaire responses, lower-limb muscle strength testing using a load cell, and vertical jump performance assessment.

The study aims to describe the prevalence, severity, type, and impact of urinary incontinence across different activity levels and sexes, and to explore potential associations with lower-limb strength, jump performance, and sport-related characteristics.

Read the detailed description

Urinary incontinence is a common condition that may affect both women and men and has been associated with physical activity and participation in high-impact sports. Although regular exercise provides substantial health benefits, repetitive increases in intra-abdominal pressure during high-impact activities may contribute to pelvic floor dysfunction in susceptible individuals. Most previous studies have focused on female athletes from specific sports, while evidence including both sexes and different physical activity levels remains limited.

This observational cross-sectional study will compare urinary incontinence characteristics among six population groups defined according to sex and physical activity level: male and female participants in high-impact sports, physically active males and females who do not participate in high-impact sports, and sedentary males and females.

Participants will attend a single face-to-face assessment session after providing written informed consent. During the visit, sociodemographic and clinical information, physical activity characteristics, sport-related variables, urinary incontinence questionnaires, and psychosocial questions related to social taboos and response honesty will be collected. Lower-limb muscle strength will be assessed using a load cell system, and jump performance will be evaluated using the My Jump 2 application.

The primary objective is to compare the prevalence, severity, type, and impact of urinary incontinence across the different study groups. Secondary analyses will explore the relationship between urinary incontinence and physical activity level, lower-limb muscle strength, jump performance, sport-related characteristics, and selected demographic and clinical variables.

Participants will be recruited through social media, institutional dissemination, and sports clubs using voluntary convenience and snowball sampling. All assessments will be performed by trained researchers following standardized procedures.

02

Conditions studied

  • Urinary Incontinence (UI)
  • Urinary Incontinence , Stress

Browse trials for

Keywords

  • urinary incontinence
  • physical activity
  • high-impact sports
03

In context

Urinary Incontinence, Stress Reclassified

651 studies on the registry are indexed under Urinary Incontinence, Stress; 120 are open to participants now.

This study's planned enrollment of 270 is above the median of 130 across 127 observational studies indexed under Urinary Incontinence, Stress.

Browse Urinary Incontinence, Stress studies →

Lead sponsor

University of Valencia is the lead sponsor of 357 studies on the registry; 75 are open to participants now.

Compared within Urinary Incontinence, Stress, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Urinary Incontinence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The study population will consist of community-dwelling adults aged 18-35 years recruited from the general population and sports clubs. Participants will include males and females who regularly participate in high-impact sports, physically active individuals who do not participate in high-impact sports, and sedentary individuals. Recruitment will be conducted through social media, institutional advertisements, sports clubs, and snowball sampling. All participants will voluntarily contact the research team and will undergo a single face-to-face assessment after providing written informed consent.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 35 years.
  • Male or female participants.
  • Able to understand and provide written .
  • Belong to one of the following groups:

Regular participation in high-impact sports (≥2 training sessions per week for at least the previous 2 years).

Physically active individuals meeting the World Health Organization recommendations (≥150 minutes/week of moderate-intensity activity, ≥75 minutes/week of vigorous-intensity activity, or an equivalent combination), without regular participation in high-impact sports.

Sedentary individuals who do not meet the World Health Organization physical activity recommendations.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or childbirth within the previous 12 months.
  • Current or recent urinary tract infection.
  • History of urogynecological disease or pelvic/urogynecological surgery.
  • (BMI) >35 kg/m².
  • Inability to understand or complete the study procedures or questionnaires in Spanish or English.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
270 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Male High-Impact Sports Participants

    Males aged 18-35 years who regularly participate in high-impact sports (at least twice per week for the previous two years).

    Diagnostic Test: No Intervention: Observational Cohort

  • Female High-Impact Sports Participants

    Females aged 18-35 years who regularly participate in high-impact sports (at least twice per week for the previous two years).

    Diagnostic Test: No Intervention: Observational Cohort

  • Physically Active Males

    Males aged 18-35 years who meet the World Health Organization physical activity recommendations but do not participate in high-impact sports.

    Diagnostic Test: No Intervention: Observational Cohort

  • Physically Active Females

    Females aged 18-35 years who meet the World Health Organization physical activity recommendations but do not participate in high-impact sports.

    Diagnostic Test: No Intervention: Observational Cohort

  • Sedentary Males

    Males aged 18-35 years who do not meet the World Health Organization physical activity recommendations.

    Diagnostic Test: No Intervention: Observational Cohort

  • Sedentary Females

    Females aged 18-35 years who do not meet the World Health Organization physical activity recommendations.

    Diagnostic Test: No Intervention: Observational Cohort

Interventions

  • Diagnostic testNo Intervention: Observational Cohort

    No intervention

06

What researchers measure

Primary outcomes

  1. Urinary incontinence severity

    Urinary incontinence severity assessed using the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF). Higher scores indicate greater symptom severity and impact on quality of life. The total score ranges from 0 to 21, with higher scores indicating more severe urinary incontinence symptoms and greater impact on quality of life.

    Time frame: Baseline (single study visit)

Secondary outcomes

  1. Urinary incontinence-related quality of life

    Quality of life associated with urinary incontinence assessed using the Incontinence Quality of Life Questionnaire (I-QOL). The total score ranges from 0 to 100, with higher scores indicating better urinary incontinence-related quality of life.

    Time frame: Baseline (single study visit)

  2. Lower-limb muscle strength

    Maximum voluntary force and mean voluntary force of hip adduction, abduction, flexion, extension, internal rotation, and external rotation measured using a load cell and ChronoJump software.

    Time frame: Baseline (single study visit)

  3. Vertical jump performance

    Vertical jump performance assessed using the My Jump 2 application.

    Time frame: Baseline (single study visit)

  4. Physical activity level

    Physical activity level assessed using the International Physical Activity Questionnaire (IPAQ). Physical activity is expressed as metabolic equivalent (MET)-minutes per week and classified into low, moderate, or high physical activity levels, according to the IPAQ scoring protocol. Higher MET-minutes per week indicate greater levels of physical activity.

    Time frame: Baseline (single study visit)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2026
First posted
Jul 17, 2026
StartActual
Sep 24, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07710508
Responsible party
Noemi Moreno-Segura (Assistant professor, University of Valencia) — Principal investigator
First posted
Jul 17, 2026
Start date
Sep 24, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion